#386 – Aging Clocks—What They Measure, How They Work, and Their Clinical and Real-World Relevance
Aging clocks, built on DNA‑methylation patterns, aim to quantify biological age as a shortcut for long‑term health outcomes. Researchers view them as surrogate endpoints that could compress 20‑year anti‑aging trials into months, helping evaluate drugs or lifestyle interventions. However, the market now offers consumer‑focused tests while scientific validation of clinical utility remains limited. Recent comparative studies pit epigenetic clocks against traditional actuarial mortality models to assess whether they truly outperform existing risk calculators.
Thinking in Trade-Offs: A Necessary Antidote to Diet Tribalism
The episode examines the pervasive diet‑tribalism that claims any single eating plan is a flawless solution, arguing instead that all diets are trade‑off‑driven optimizations against the typical American diet, which is high in excess calories, refined carbs, and ultra‑processed foods....
Protect the Eyes, Protect the Brain—A Potentially Simple Lever for Dementia Risk
Neurodegeneration leading to dementia could affect up to 152 million people worldwide by 2050. A recent meta‑analysis of more than 540,000 older adults found cataract surgery reduces the risk of cognitive impairment or dementia by roughly 25 % compared with untreated cataracts,...
#385 – AMA #82: Applying the Tools of Longevity in the Real World: Disease Prevention, DEXA Scans, Artificial Sweeteners, Injury...
In this AMA episode, Dr. Peter Atiyah tackles a wide array of practical health questions, covering how health priorities shift across the decades, the hierarchy of chronic disease risk, and the most useful consumer health metrics. He discusses the role...
When Sophisticated Models Meet Questionable Premises
A recent Mendelian randomization (MR) study attempted to determine whether low‑calorie, vegetarian, or gluten‑free diets causally influence inflammatory skin diseases such as psoriasis, psoriatic arthritis, atopic dermatitis, and acne. Using genetic variants from the UK Biobank as proxies for self‑reported...
#384 – Special Episode — Obicetrapib: The CETP Inhibitor with Cardiovascular Benefits and Potential Alzheimer’s Prevention
Obicetrapib, a next‑generation CETP inhibitor, has demonstrated potent LDL‑C, apoB, and Lp(a) reductions in a large phase III lipid trial. A pre‑specified biomarker sub‑study reported a marked attenuation of p‑tau217 progression, especially among APOE4/4 carriers, hinting at a potential Alzheimer’s‑related benefit....
An Intriguing Case of “Exceptional Resilience” Against Dementia
Researchers documented a 75‑year‑old man, Doug Whitney, who carries a highly penetrant PSEN2 mutation that typically causes early‑onset Alzheimer’s disease, yet he remains cognitively normal. Imaging revealed massive amyloid buildup but tau pathology confined to the occipital lobe, an atypical...
#382 ‒ AMA #80: Longevity Optimization Through Strength Benchmarks, VO₂ Max Targets, Nutrition Principles, Brain Health, Supplements, GLP-1 RAs, Wearables,...
In this AMA episode, host Peter Atiyah answers listener questions on practical longevity strategies, covering strength metrics (relative strength, grip, lower‑body power), starter exercise routines for time‑pressed beginners, and the role of complex movement for brain health. He emphasizes normalized...
Does Lowering Cholesterol Harm the Brain?
The brain houses about 20‑25% of the body’s cholesterol, yet it relies on local synthesis because circulating cholesterol cannot cross the blood‑brain barrier. Although some patients report transient brain fog on statins, large observational studies generally show neutral or even...
GLP-1 Drugs Fail to Slow Cognitive Decline in Alzheimer’s Disease
Recent randomized trials testing GLP‑1 receptor agonists such as semaglutide and liraglutide in Alzheimer’s disease patients found no measurable slowing of cognitive decline. Earlier post‑hoc and observational analyses had suggested roughly a 50 % reduction in dementia incidence, raising hopes of...